Vaibhav Sahai Profile | University of ...

Dr. Vaibhav Sahai, MBBS, MS

Claim this profile

University of Michigan Comprehensive Cancer Center

Studies Pancreatic Cancer
Studies Bile Duct Cancer
16 reported clinical trials
28 drugs studied

Area of expertise

1Pancreatic Cancer
Vaibhav Sahai, MBBS, MS has run 10 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRCA1 positive
2Bile Duct Cancer
Vaibhav Sahai, MBBS, MS has run 4 trials for Bile Duct Cancer. Some of their research focus areas include:
FGFR2 positive
Stage IV
RAF positive

Affiliated Hospitals

Image of trial facility.
University Of Michigan Comprehensive Cancer Center
Image of trial facility.
Rogel Cancer Center

Clinical Trials Vaibhav Sahai, MBBS, MS is currently running

Image of trial facility.

Atezolizumab + Chemotherapy

for Neuroendocrine Carcinoma

This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
Image of trial facility.

Durvalumab + Olaparib with Radiation

for Pancreatic Cancer

This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. The combination of targeted therapy with olaparib, immunotherapy with durvalumab and radiation therapy may stimulate an anti-tumor immune response and promote tumor control in locally advanced unresectable pancreatic cancer.
Recruiting1 award Phase 125 criteria

More about Vaibhav Sahai, MBBS, MS

Clinical Trial Related6 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Vaibhav Sahai, MBBS, MS has experience with
  • Cisplatin
  • Nivolumab
  • Capecitabine
  • Carboplatin
  • Etoposide
  • Temozolomide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Vaibhav Sahai, MBBS, MS specialize in?
Is Vaibhav Sahai, MBBS, MS currently recruiting for clinical trials?
Are there any treatments that Vaibhav Sahai, MBBS, MS has studied deeply?
What is the best way to schedule an appointment with Vaibhav Sahai, MBBS, MS?
What is the office address of Vaibhav Sahai, MBBS, MS?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security